Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pulse Biosciences ( (PLSE) ) has provided an update.
On February 19, 2026, Pulse Biosciences entered into a new equity distribution agreement with TD Securities (USA) LLC, allowing the company to sell up to approximately $60 million of its common stock from time to time in at-the-market and other permitted transactions under its existing shelf registration. The company is not obligated to sell any shares, can suspend offers at its discretion, and will pay TD Cowen up to a 3% commission on gross sales, positioning Pulse Biosciences with a refreshed, flexible equity financing channel after terminating a prior at-the-market offering program on February 18, 2026 that still had the same dollar amount remaining unsold.
The termination of the earlier equity distribution agreement and immediate establishment of the new program with TD Cowen effectively roll over the unused capacity for future issuance, helping the company preserve access to incremental capital without committing to a specific financing timeline. This structure may influence shareholder dilution over time, depending on market conditions and the extent to which management chooses to utilize the program for funding its ongoing activities and potential growth initiatives.
The most recent analyst rating on (PLSE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is held down primarily by very weak financial performance (minimal revenue, negative gross profit, large losses, and persistent cash burn), with a downtrend-leaning technical setup adding pressure. Offsetting this somewhat are a comparatively low-leverage balance sheet and a more constructive earnings-call backdrop driven by trial/regulatory progress and early commercial traction.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a U.S.-listed company whose shares of common stock trade on The Nasdaq Capital Market, giving it access to public equity markets for corporate financing. The company utilizes shelf registration statements on Form S-3 to maintain flexibility in issuing additional common stock as needed to support its strategic and operational objectives.
Average Trading Volume: 278,141
Technical Sentiment Signal: Buy
Current Market Cap: $1.6B
Find detailed analytics on PLSE stock on TipRanks’ Stock Analysis page.